comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-12 09:10:23 - browse：1271

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Arena BioWorks launches in Cambridge to speed drug discovery

hotspot

WSS

NVIDIA and Google execs on the future of AI and drug discovery

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Helping hospitals and community health centers plan for resilience

Allen Institute goes after foundational questions, CEO Costa says

American taxpayers paid $1.8 trillion in health care costs in 2022

Medicare Advantage coverage denials need scrutiny, senators say

entertainment

comprehensive

focus

Anesthesiologist group: stop taking Ozempic before surgery

Study suggests new cause of Down syndrome: cells linked to aging

In age of alternative facts, a scholarly course on calling out crap

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Novavax promises a turnaround & Lilly roils the obesity market

Profiling embryos to choose those with higher IQs is almost a reality

Anesthesiologist group: stop taking Ozempic before surgery

Stories you might have missed in 2023: health, science, medicine

Alkermes shareholders re

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

hotspot

Helping hospitals and community health centers plan for resilience

Case highlights the risks of experimental stem cell therapy

A preacher's new calling: Diversifying neuroscience research

With measles on the rise, a personal story of a devastating disease

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Addiction experts warn against a second 'war on drugs'

hotspot

focus

explore

Wikipedia